{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:59:58Z","timestamp":1790369998319,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40265-026-02368-0","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T06:14:08Z","timestamp":1786601648000},"page":"1723-1733","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lenacapavir: A Review in HIV Pre-Exposure Prophylaxis"],"prefix":"10.1007","volume":"86","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"issue":"5","key":"2368_CR1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399\u2013410.","journal-title":"N Engl J Med"},{"issue":"27","key":"2368_CR2","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587\u201399.","journal-title":"N Engl J Med"},{"issue":"10246","key":"2368_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","volume":"396","author":"KH Mayer","year":"2020","unstructured":"Mayer KH, Molina JM, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396(10246):239\u201354.","journal-title":"Lancet"},{"issue":"8","key":"2368_CR4","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jama.2023.9865","volume":"330","author":"R Chou","year":"2023","unstructured":"Chou R, Spencer H, Bougatsos C, et al. Preexposure prophylaxis for the prevention of HIV: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2023;330(8):746\u201363.","journal-title":"JAMA"},{"issue":"4","key":"2368_CR5","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3018(22)00030-3","volume":"9","author":"J Zhang","year":"2022","unstructured":"Zhang J, Li C, Xu J, et al. Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis. Lancet HIV. 2022;9(4):e254\u201368.","journal-title":"Lancet HIV"},{"issue":"2","key":"2368_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/cpt.3447","volume":"117","author":"NC Neverette","year":"2025","unstructured":"Neverette NC, Dumond JB, McMahon DK, et al. Lenacapavir: playing the long game in the new era of antiretrovirals. Clin Pharmacol Ther. 2025;117(2):353\u201367.","journal-title":"Clin Pharmacol Ther"},{"issue":"14","key":"2368_CR7","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s40265-022-01791-3","volume":"82","author":"HA Blair","year":"2022","unstructured":"Blair HA. Cabotegravir extended-release injectable suspension: a review in HIV-1 pre-exposure prophylaxis. Drugs. 2022;82(14):1489\u201398.","journal-title":"Drugs"},{"issue":"10337","key":"2368_CR8","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779\u201389.","journal-title":"Lancet"},{"issue":"7","key":"2368_CR9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595\u2013608.","journal-title":"N Engl J Med"},{"issue":"3","key":"2368_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/10600280251379877","volume":"60","author":"DE Koren","year":"2026","unstructured":"Koren DE, Chahine EB, Sherman EM. Lenacapavir: a twice-yearly injectable for HIV preexposure prophylaxis. Ann Pharmacother. 2026;60(3):276\u201386.","journal-title":"Ann Pharmacother"},{"key":"2368_CR11","first-page":"1","volume":"15","author":"IA Taylor","year":"2023","unstructured":"Taylor IA, Fassati A. The capsid revolution. J Mol Cell Biol. 2023;15:1\u201311.","journal-title":"J Mol Cell Biol"},{"issue":"8","key":"2368_CR12","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1038\/s41564-025-02054-z","volume":"10","author":"Z Hou","year":"2025","unstructured":"Hou Z, Shen Y, Fronik S, et al. HIV-1 nuclear import is selective and depends on both capsid elasticity and nuclear pore adaptability. Nat Microbiol. 2025;10(8):1868\u201385.","journal-title":"Nat Microbiol"},{"issue":"4","key":"2368_CR13","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.cell.2024.12.008","volume":"188","author":"JP Kreysing","year":"2025","unstructured":"Kreysing JP, Heidari M, Zila V, et al. Passage of the HIV capsid cracks the nuclear pore. Cell. 2025;188(4):930-43.e21.","journal-title":"Cell"},{"key":"2368_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117125","author":"E De Clercq","year":"2025","unstructured":"De Clercq E, Zhang Y, Li G, et al. Lenacapavir: a capsid inhibitor for HIV-1 treatment and prevention. Biochem Pharmacol. 2025. https:\/\/doi.org\/10.1016\/j.bcp.2025.117125.","journal-title":"Biochem Pharmacol"},{"key":"2368_CR15","unstructured":"Gilead Sciences Inc. YEZTUGO\u00ae (lenacapavir) tablets, for oral use, and YEZTUGO\u00ae (lenacapavir) injection, for subcutaneous use: US prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/220018s000lbl.pdf. Accessed 15 July 2026."},{"key":"2368_CR16","unstructured":"European Medicines Agency. Yeytuo (lenacapavir) solution for injection: EU summary of product characteristics. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/yeytuo-epar-product-information_en.pdf. Accessed 15 July 2026."},{"issue":"14","key":"2368_CR17","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s40265-022-01786-0","volume":"82","author":"J Paik","year":"2022","unstructured":"Paik J. Lenacapavir: first approval. Drugs. 2022;82(14):1499\u2013504.","journal-title":"Drugs"},{"issue":"12","key":"2368_CR18","doi-asserted-by":"publisher","first-page":"6213","DOI":"10.1021\/acs.molpharmaceut.3c00626","volume":"20","author":"R Subramanian","year":"2023","unstructured":"Subramanian R, Tang J, Zheng J, et al. Lenacapavir: a novel, potent, and selective first-in-class inhibitor of HIV-1 capsid function exhibits optimal pharmacokinetic properties for a long-acting injectable antiretroviral agent. Mol Pharm. 2023;20(12):6213\u201325.","journal-title":"Mol Pharm"},{"issue":"7822","key":"2368_CR19","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","volume":"584","author":"JO Link","year":"2020","unstructured":"Link JO, Rhee MS, Tse WC, et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature. 2020;584(7822):614\u20138.","journal-title":"Nature"},{"issue":"16","key":"2368_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI167818","volume":"133","author":"E Bekerman","year":"2023","unstructured":"Bekerman E, Yant SR, VanderVeen L, et al. Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model. J Clin Invest. 2023;133(16):1\u20139.","journal-title":"J Clin Invest"},{"issue":"5","key":"2368_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.70254","volume":"15","author":"H-y Kim","year":"2025","unstructured":"Kim H-y, Liebenberg A, Zhang L, et al. Pharmacokinetics, pharmacodynamics, efficacy and drug resistance selection of injectable long-acting lenacapavir pre-exposure prophylaxis (PrEP) against HIV. CPT Pharmacometr Syst Pharmacol. 2025;15(5):e70254.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"1","key":"2368_CR22","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1093\/infdis\/jiaf533","volume":"233","author":"S Cox","year":"2025","unstructured":"Cox S, Andreatta K, Hendricks MR, et al. Resistance analyses of lenacapavir, emtricitabine\/tenofovir alafenamide and emtricitabine\/tenofovir disoproxil fumarate in the PURPOSE 1 and 2 studies. J Infect Dis. 2025;233(1):e203\u201311.","journal-title":"J Infect Dis"},{"key":"2368_CR23","unstructured":"Cox S, Andreatta K, Hendricks MR, et al. Resistance analysis of the PURPOSE studies through the end of the randomized blinded phase [abstract no. 130 plus oral presentation]. In: Conference on Retroviruses and Opportunistic Infections. 2026."},{"issue":"2","key":"2368_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40262-023-01328-1","volume":"63","author":"E Weber","year":"2024","unstructured":"Weber E, Subramanian R, Rowe W, et al. Pharmacokinetics, disposition, and biotransformation of [14C]lenacapavir, a novel, first-in-class, selective inhibitor of HIV-1 capsid function, in healthy participants following a single intravenous infusion. Clin Pharmacokinet. 2024;63(2):241\u201353.","journal-title":"Clin Pharmacokinet"},{"key":"2368_CR25","unstructured":"Imperial M, Arora P, Gill K, et al. Pharmacokinetic analyses to support extrapolation of efficacy from adults to adolescents for lenacapavir for HIV prevention [abstract no. 101]. Clin Pharmacol Drug Dev. 2025;14(S1):22\u20134."},{"key":"2368_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(26)00112-8","author":"LG Bekker","year":"2026","unstructured":"Bekker LG, Moodley D, Diallo DD, et al. HIV acquisitions, safety, and pharmacokinetics of lenacapavir for HIV pre-exposure prophylaxis in pregnant and lactating women (PURPOSE 1): a substudy of a phase 3, randomised controlled trial. Lancet HIV. 2026. https:\/\/doi.org\/10.1016\/S2352-3018(26)00112-8.","journal-title":"Lancet HIV."},{"issue":"4","key":"2368_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/aac.01344-23","volume":"68","author":"V Jogiraju","year":"2024","unstructured":"Jogiraju V, Weber E, Hindman J, et al. Pharmacokinetics of long-acting lenacapavir in participants with hepatic or renal impairment. Antimicrob Agents Chemother. 2024;68(4):1\u201312.","journal-title":"Antimicrob Agents Chemother"},{"key":"2368_CR28","unstructured":"Avihingsanon A, Ogbuagu O, Frank I, et al. Commonly prescribed concomitant medications and clinical safety findings with lenacapavir for pre-exposure prophylaxis in PURPOSE 2 [abstract no. MeP16.1]. HIV Med. 2025;26(S4):179\u201381."},{"key":"2368_CR29","doi-asserted-by":"crossref","unstructured":"Potloane D, Louw CE, Kigozi G, et al. No clinically significant drug\u2013drug interactions between lenacapavir and hormonal contraceptives in PURPOSE 1 [abstract no. P-299 plus poster]. In: IDWeek 2025. 2025.","DOI":"10.1093\/ofid\/ofaf695.519"},{"key":"2368_CR30","doi-asserted-by":"crossref","unstructured":"Blumenthal J, Acevedo-Quifiones M, Phanuphak N, et al. No clinically significant drug-drug interactions with coadministration of feminizing or masculinizing hormone therapy and twice-yearly lenacapavir PrEP in gender-diverse persons [abstract no. P-305 plus poster]. In: IDWeek 2025. 2025.","DOI":"10.1093\/ofid\/ofaf695.525"},{"key":"2368_CR31","unstructured":"Imperial M, Hughes E, Panchia R, et al. Population pharmacokinetic analysis of lenacapavir in people who want or need pre-exposure prophylaxis [abstract no. I-109 plus poster]. In: Population Approach Group Europe (PAGE) meeting. 2025."},{"key":"2368_CR32","doi-asserted-by":"crossref","unstructured":"Clark J, Agwu AL, Buchbiner S, et al. Favorable adherence and safety of twice-yearly subcutaneous lenacapavir for PrEP among PURPOSE 2 participants who used substances [abstract no. 392 plus presentation]. In: IDWeek 2025. 2025.","DOI":"10.1093\/ofid\/ofaf695.130"},{"key":"2368_CR33","unstructured":"Sun H, Le H, Salerno S, et al. Low potential for drug interaction between lenacapavir and fentanyl [abstract no. PI-019]. Clin Pharmacol Ther. 2025;117(S1)."},{"issue":"13","key":"2368_CR34","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","volume":"392","author":"CF Kelley","year":"2025","unstructured":"Kelley CF, Acevedo-Qui\u00f1ones M, Agwu AL, et al. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N Engl J Med. 2025;392(13):1261\u201376.","journal-title":"N Engl J Med"},{"issue":"13","key":"2368_CR35","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","volume":"391","author":"LG Bekker","year":"2024","unstructured":"Bekker LG, Das M, Abdool Karim Q, et al. Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women. N Engl J Med. 2024;391(13):1179\u201392.","journal-title":"N Engl J Med"},{"key":"2368_CR36","unstructured":"Ndlovu N, Malahleha M, Singh Y, et al. Twice-yearly subcutaneous lenacapavir for PrEP: updated HIV-1 incidence & safety data in PURPOSE 1 at the end of the randomized blinded phase [abstract no. 128 plus oral presentation]. In: Conference on Retroviruses and Opportunistic Infections. 2026."},{"key":"2368_CR37","unstructured":"Cantos VD, Mngadi K, Supparatpinyo K, et al. Lenacapavir for PrEP: HIV-1 incidence and safety from PURPOSE 2 at the end of the randomized blinded phase [abstract no. 129 plus oral presentation]. In: Conference on Retroviruses and Opportunistic Infections. 2026."},{"key":"2368_CR38","unstructured":"World Health Organization. Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis (PrEP). 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240111608. Accessed 15 July 2026."},{"issue":"7","key":"2368_CR39","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/jama.2024.24543","volume":"333","author":"RT Gandhi","year":"2024","unstructured":"Gandhi RT, Landovitz RJ, Sax PE, et al. Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society-USA Panel. JAMA. 2024;333(7):609\u201328.","journal-title":"JAMA"},{"key":"2368_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.11604\/pamj.2024.47.102.36052","volume":"47","author":"S Owuor","year":"2024","unstructured":"Owuor S, Kimani M, Kaplan R. The future of PrEP: novel long-acting HIV prevention agents for adolescent women. Pan Afr Med J. 2024;47:1\u20135.","journal-title":"Pan Afr Med J"},{"key":"2368_CR41","unstructured":"UNAIDS HIV Prevention Coalition. PrEP target\u2011setting for key and high\u2011priority populations: estimating the number at risk. 2021. https:\/\/hivpreventioncoalition.unaids.org\/sites\/default\/files\/attachments\/1.PrEP-target-setting_online.pdf. Accessed 15 July 2026."},{"issue":"35","key":"2368_CR42","doi-asserted-by":"publisher","first-page":"541","DOI":"10.15585\/mmwr.mm7435a1","volume":"74","author":"RR Patel","year":"2025","unstructured":"Patel RR, Hoover KW, Lale A, et al. Clinical recommendation for the use of injectable lenacapavir as HIV preexposure prophylaxis\u2014United States, 2025. MMWR Morb Mortal Wkly Rep. 2025;74(35):541\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2368_CR43","unstructured":"European AIDS Clinical Society. EACS guidelines: pre-exposure prophylaxis (PrEP). 2025. https:\/\/eacs.sanfordguide.com\/en\/eacs-hiv\/art\/eacs-pre-exposure-prophylaxis. Accessed 15 July 2026."},{"issue":"1","key":"2368_CR44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/cpt.2830","volume":"114","author":"N Parkin","year":"2023","unstructured":"Parkin N, Gao F, Grebe E, et al. Facilitating next-generation pre-exposure prophylaxis clinical trials using HIV recent infection assays: a consensus statement from the forum HIV Prevention Trial Design Project. Clin Pharmacol Ther. 2023;114(1):29\u201340.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"2368_CR45","doi-asserted-by":"publisher","first-page":"e732","DOI":"10.1016\/S2352-3018(25)00128-6","volume":"12","author":"G van Zyl","year":"2025","unstructured":"van Zyl G, Prochazka M, Schmidt HA, et al. Lenacapavir-associated drug resistance: implications for scaling up long-acting HIV pre-exposure prophylaxis. Lancet HIV. 2025;12(10):e732\u20136.","journal-title":"Lancet HIV."},{"issue":"7","key":"2368_CR46","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1093\/jac\/dkae115","volume":"79","author":"M Wirden","year":"2024","unstructured":"Wirden M, Pouderoux C, Peytavin G, et al. Ultra-rapid selection of the N74D capsid inhibitor resistance mutation after 3 weeks on lenacapavir. J Antimicrob Chemother. 2024;79(7):1706\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"2368_CR47","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1016\/S2352-3018(23)00079-6","volume":"10","author":"JE Haberer","year":"2023","unstructured":"Haberer JE, Mujugira A, Mayer KH. The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities. Lancet HIV. 2023;10(6):e404\u201311.","journal-title":"Lancet HIV."},{"key":"2368_CR48","unstructured":"Mansoor LE, Batting J, Kiwanuka N, et al. PURPOSE 1: preference for twice-yearly injection vs daily oral pills for HIV PrEP in cisgender women [abstract no. 1230]. Top Antivir Med. 2025;33(1):403\u20134."},{"key":"2368_CR49","unstructured":"Mngadi K, Phanuphak N, Hinojosa JC, et al. Preference for twice-yearly injections versus daily oral pills for HIV PrEP in cisgender men, transgender women, transgender men and gender nonbinary people enrolled in PURPOSE 2 [abstract no. OAC0504 plus presentation]. J Int AIDS Soc. 2025;28(S4):33\u20134."},{"key":"2368_CR50","unstructured":"Montgomery EL, Gill K, Hardwick TS, et al. Qualitative assessment of acceptability and preferences for injectable and oral PrEP in PURPOSE 1 [abstract no. 1234]. Top Antivir Med. 2025;33(1):405."},{"key":"2368_CR51","unstructured":"European Medicines Agency. Dapivirine vaginal ring 25 mg vaginal delivery system: EU summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/. Accessed 15 July 2026."},{"key":"2368_CR52","unstructured":"US National Institutes of Health. ClinicalTrials.gov. 2026. https:\/\/clinicaltrials.gov\/. Accessed 15 July 2026."},{"issue":"1","key":"2368_CR53","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/COH.0000000000000900","volume":"20","author":"A Tembo","year":"2025","unstructured":"Tembo A, Venter WDF, Sokhela S. Long-acting antiretroviral therapy in low-income and middle-income countries: considerations for roll-out. Curr Opin HIV AIDS. 2025;20(1):19\u201324.","journal-title":"Curr Opin HIV AIDS"},{"key":"2368_CR54","unstructured":"US National Institutes of Health. ClinicalTrials identifier NCT07218211. 2025. https:\/\/clinicaltrials.gov\/study\/NCT07218211. Accessed 9 Apr 2026."},{"issue":"9","key":"2368_CR55","volume":"17","author":"K Sanaullah","year":"2025","unstructured":"Sanaullah K, Hasan AH, Abid MA. FDA-approved HIV-1 capsid inhibition with lenacapavir: a paradigm shift in pre-exposure prophylaxis. Cureus. 2025;17(9):e92043.","journal-title":"Cureus"},{"issue":"2","key":"2368_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jia2.26427","volume":"28","author":"D Kaftan","year":"2025","unstructured":"Kaftan D, Sharma M, Resar D, et al. Cost thresholds for anticipated long-acting HIV pre-exposure prophylaxis products in Eastern and Southern Africa: a mathematical modelling study. J Int AIDS Soc. 2025;28(2):1\u20139.","journal-title":"J Int AIDS Soc"},{"issue":"11","key":"2368_CR57","doi-asserted-by":"publisher","first-page":"e765","DOI":"10.1016\/S2352-3018(24)00239-X","volume":"11","author":"L Wu","year":"2024","unstructured":"Wu L, Kaftan D, Wittenauer R, et al. Health impact, budget impact, and price threshold for cost-effectiveness of lenacapavir for HIV pre-exposure prophylaxis in eastern and southern Africa: a modelling analysis. Lancet HIV. 2024;11(11):e765\u201373.","journal-title":"Lancet HIV"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02368-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02368-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02368-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:07:08Z","timestamp":1790366828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02368-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2368"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02368-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hannah A. Blair is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}